翻訳と辞書 |
Bimagrumab
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.〔(【引用サイトリンク】url=http://www.novartis.com/newsroom/media-releases/en/2013/1723765.shtml )〕 Bimagrumab is currently entering Phase II development, with some research indicating clinical effects.〔(Treatment of sporadic inclusion body myositis with bimagrumab ). Retrieved 20 April 2015.〕 In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.〔(Novartis: Planned filings 2015 to >=2019 ). Retrieved 27 May 2015.〕 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Bimagrumab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|